Synergistic risk and decision making: A study of whether knowledge of harmful drug-drug interactions affects drug dosing behaviours
Synergistic risk and decision making: A study of whether knowledge of harmful drug-drug interactions affects drug dosing behaviours
Recent studies indicate that nearly 70% of the adult population in developed countries now use medicinal drugs, over 20% are prescribed five or more drugs, and approximately 12% are exposed to potentially serious drug-drug interactions. The day-to-day responsibility of safely using combinations of medicinal drugs often rest with lay individuals acting in non-clinical contexts without professional supervision. Consequently, understanding that certain drug combinations present a ‘synergistic risk’ (i.e., the risk attributable to the drug combination is greater than the sum of the risk attributable to each constituent drug) is often central to avoiding harmful drug-drug interactions. We conducted two studies to test whether providing individuals with information about a drug combination that presents a synergistic (cf. additive) risk elicited higher perceived risk and, therefore, increased precautionary dosing behaviours. Participants were presented with a scenario describing how two symptoms of an infection that could each be treated by a different drug. In Experiment 1 (N = 120), information about the effects of combining the two drugs was varied: (i) no information, (ii) combination elicits an additive risk, or (iii) combination elicits a synergistic risk. In Experiment 2 (N = 445), the size of the risk (small or large) and the participant’s role (patient or doctor) was also varied. In both studies, perceived risk and negative affect increased in response to information about the increased probability of side effects from the harmful synergistic drug interaction. Despite these increases, participants did not adjust their drug dosing behaviour in either experiment: dosing was similar when these interactions were large or small, or when they had synergistic or additive effects. These findings suggest that people may struggle to transfer their knowledge of drug-drug interaction risks into decision making behaviours. Hence, both researchers and medical professionals should take care not to assume that holding accurate risk perceptions of a drug’s side effects will result in decisions that help to avoid harmful drug interactions.
Synergistic risk, decision making, risk perception, risk communication, drug administration
Dawson, Ian
dff1b440-6c83-4354-92b6-04809460b01a
Dohle, Simone
fa7225d8-1dd1-454f-8153-f3da8711191c
21 June 2017
Dawson, Ian
dff1b440-6c83-4354-92b6-04809460b01a
Dohle, Simone
fa7225d8-1dd1-454f-8153-f3da8711191c
Dawson, Ian and Dohle, Simone
(2017)
Synergistic risk and decision making: A study of whether knowledge of harmful drug-drug interactions affects drug dosing behaviours.
26th Annual Conference/Meeting of the Society for Risk Analysis – Europe (SRA-E), , Lisbon, Portugal.
19 - 21 Jun 2017.
Record type:
Conference or Workshop Item
(Paper)
Abstract
Recent studies indicate that nearly 70% of the adult population in developed countries now use medicinal drugs, over 20% are prescribed five or more drugs, and approximately 12% are exposed to potentially serious drug-drug interactions. The day-to-day responsibility of safely using combinations of medicinal drugs often rest with lay individuals acting in non-clinical contexts without professional supervision. Consequently, understanding that certain drug combinations present a ‘synergistic risk’ (i.e., the risk attributable to the drug combination is greater than the sum of the risk attributable to each constituent drug) is often central to avoiding harmful drug-drug interactions. We conducted two studies to test whether providing individuals with information about a drug combination that presents a synergistic (cf. additive) risk elicited higher perceived risk and, therefore, increased precautionary dosing behaviours. Participants were presented with a scenario describing how two symptoms of an infection that could each be treated by a different drug. In Experiment 1 (N = 120), information about the effects of combining the two drugs was varied: (i) no information, (ii) combination elicits an additive risk, or (iii) combination elicits a synergistic risk. In Experiment 2 (N = 445), the size of the risk (small or large) and the participant’s role (patient or doctor) was also varied. In both studies, perceived risk and negative affect increased in response to information about the increased probability of side effects from the harmful synergistic drug interaction. Despite these increases, participants did not adjust their drug dosing behaviour in either experiment: dosing was similar when these interactions were large or small, or when they had synergistic or additive effects. These findings suggest that people may struggle to transfer their knowledge of drug-drug interaction risks into decision making behaviours. Hence, both researchers and medical professionals should take care not to assume that holding accurate risk perceptions of a drug’s side effects will result in decisions that help to avoid harmful drug interactions.
This record has no associated files available for download.
More information
Accepted/In Press date: 6 March 2017
Published date: 21 June 2017
Venue - Dates:
26th Annual Conference/Meeting of the Society for Risk Analysis – Europe (SRA-E), , Lisbon, Portugal, 2017-06-19 - 2017-06-21
Keywords:
Synergistic risk, decision making, risk perception, risk communication, drug administration
Organisations:
Decision Analytics & Risk
Identifiers
Local EPrints ID: 411979
URI: http://eprints.soton.ac.uk/id/eprint/411979
PURE UUID: 89a02215-62c4-4d60-a1be-0191fb2db498
Catalogue record
Date deposited: 04 Jul 2017 16:31
Last modified: 12 Dec 2021 03:52
Export record
Contributors
Author:
Simone Dohle
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics